Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

FIT Hon Teng: IPO Relaunched, What's New and So What?

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>FIT Hon Teng, a subsidiary of Taiwan listed <a href="https://www.smartkarma.com/entities/745" target="_blank" data-smartkarma-citation="entities:745:1">Hon Hai Precision Industry (2317 TT)</a>, is planning to raise US$1-1.5bn to expand its business. </p><p>In this insight, I will look at FIT's competitiveness and related party transaction, its recent acquisition of Avago's optical module business, and compare FIT's financial and operational metrics with other listed subsidiaries of Hon Hai. </p>

FIT Hon Teng, a subsidiary of Taiwan listed Hon Hai Precision Industry (2317 TT), is planning to raise US$1-1.5bn to expand its business. In this insight, I will look at FIT's competitiveness and related party transaction, its recent acquisition of Avago's optical module business, and compare FIT's financial and operational metrics with other listed subsidiaries of Hon Hai. 

FIT Hon Teng IPO Early Thought: Parent Hon Hai Has a Different Focus